List of Excipients in Branded Drug DEXTROSE MONOHYDRATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	DEXTROSE MONOHYDRATE	dextrose monohydrate	51662-1493	WATER

Generic Drugs Containing DEXTROSE MONOHYDRATE

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA HealthFirst	dextrose monohydrate	51662-1584	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	dextrose monohydrate	51662-1584	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA HealthFirst	dextrose monohydrate	51662-1584	WATER
REMEDYREPACK INC	dextrose monohydrate	70518-4159	HYDROCHLORIC ACID
REMEDYREPACK INC	dextrose monohydrate	70518-4159	SODIUM HYDROXIDE
REMEDYREPACK INC	dextrose monohydrate	70518-4159	WATER

What are the Most Frequently-Used Excipients in DEXTROSE MONOHYDRATE?

# Of NDCs	Excipient
4	HYDROCHLORIC ACID
4	SODIUM HYDROXIDE
4	WATER

Dextrose Monohydrate Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Dextrose monohydrate is a low-cost, high-volume pharmaceutical ingredient used primarily as an active carbohydrate source in parenteral nutrition, hypoglycemia treatment, irrigation products, and oral dosage forms. Its commercial value comes from manufacturing scale, pharmacopeial compliance, sterile-fill capability, and supply reliability rather than from exclusivity.

The strongest opportunities are in high-purity injectable grades, ready-to-administer premixed solutions, dual-chamber nutrition products, oral solid-dose excipient systems, and contract manufacturing. Conventional dextrose monohydrate has limited patent protection. Product differentiation depends on formulation performance, packaging, quality systems, regulatory approvals, and customer-specific supply agreements.

What is dextrose monohydrate and how is it used pharmaceutically?

Dextrose monohydrate is the monohydrate form of D-glucose. It is also known as glucose monohydrate and corresponds to CAS Registry Number 5996-10-1. Its molecular formula is C6H12O6·H2O, with a molecular weight of approximately 198.17 g/mol. The anhydrous form has a molecular weight of approximately 180.16 g/mol.

Dextrose monohydrate is used in two distinct roles:

1. As an active pharmaceutical ingredient, where glucose supplies calories or rapidly increases blood glucose.
2. As an excipient, where it provides bulk, sweetness, compressibility, or carbohydrate content in a formulation.

Primary pharmaceutical applications

Application	Function of dextrose monohydrate	Typical commercial form
Intravenous dextrose	Treatment of hypoglycemia and caloric supplementation	Sterile aqueous injection or infusion
Parenteral nutrition	Carbohydrate energy source	Large-volume infusion bag
Oral glucose products	Rapid glucose replacement	Gel, tablet, powder, or liquid
Dialysis and irrigation solutions	Osmotic agent or carbohydrate source	Sterile solution
Solid oral dosage forms	Diluent, binder, sweetener, and compressibility aid	Tablet, lozenge, powder
Pediatric and geriatric products	Palatability and energy source	Oral solution, powder, or chewable dosage form
Bioprocessing and cell-culture media	Carbon source	GMP-grade raw material or process ingredient

FDA labeling identifies dextrose injection products for indications including hypoglycemia and carbohydrate supply when oral intake is insufficient. Concentrations include 5%, 10%, 20%, and 50%, although available strengths vary by manufacturer and presentation (U.S. Food and Drug Administration [FDA], 2024a; DailyMed, 2024a).

What excipient strategy is appropriate for dextrose monohydrate products?

The formulation strategy depends on whether dextrose is the therapeutic ingredient or a supporting excipient. In injectable products, the key design variables are concentration, osmolality, pH, sterilization, container compatibility, and microbial control.

Injectable formulations

Dextrose injections are aqueous solutions that require tight control of:

• Assay and related substances
• Osmolality
• pH
• Particulate matter
• Bacterial endotoxins
• Sterility
• Container closure integrity
• Extractables and leachables
• Color and visible contamination
• Stability during terminal sterilization and storage

Dextrose monohydrate contributes water of crystallization. Formulators must calculate the weighed quantity against the desired dextrose concentration and the applicable labeling convention. A formulation intended to deliver a specified amount of anhydrous dextrose cannot be designed by treating dextrose monohydrate and anhydrous dextrose as interchangeable on a weight-for-weight basis.

High-concentration dextrose injections are hypertonic. Peripheral administration can create vein irritation and tissue injury if extravasation occurs. Higher-strength products are commonly used through central venous access, depending on the label and clinical setting. The formulation therefore has commercial value when combined with safe delivery systems, clear labeling, and appropriate hospital-use packaging.

Oral formulations

In tablets, lozenges, gels, and powders, dextrose monohydrate can provide:

• Rapidly available carbohydrate
• Sweetness
• Tablet mass
• Improved mouthfeel
• Compression support
• A recognizable glucose-based product identity

The major formulation risks are hygroscopicity, caking, Maillard-type reactions with amino-containing ingredients, and moisture-driven changes in hardness or dissolution. Moisture-barrier packaging may be required for powders and chewable products. Direct compression performance depends on particle size, morphology, flow, and compaction behavior.

A co-processed excipient system combining dextrose monohydrate with a compressibility aid or flow modifier can create a more differentiated product than commodity dextrose alone. Such systems may support proprietary formulation claims if they produce measurable advantages in tablet strength, disintegration, dissolution, or manufacturability.

What pharmacopeial and FDA requirements apply?

Dextrose monohydrate used in pharmaceutical products should conform to the relevant compendial monograph, typically the United States Pharmacopeia-National Formulary, European Pharmacopoeia, or Japanese Pharmacopoeia, depending on the target market.

The principal quality attributes include:

Quality attribute	Commercial relevance
Identity	Confirms glucose and hydrate form
Assay	Controls active or excipient strength
Water content	Distinguishes monohydrate behavior and supports stability
Optical rotation	Helps confirm stereochemical identity and purity
Related sugars	Limits process-derived impurities
Heavy metals or elemental impurities	Supports ICH Q3D compliance
Microbial limits	Required for nonsterile products
Endotoxins and sterility	Required for injectable products
Particle-size distribution	Affects blending, flow, dissolution, and filling
Bulk and tapped density	Affects tablet and powder processing
Residual solvents	Controls manufacturing-related impurities

For injectable products, the FDA may review dextrose monohydrate as the active ingredient rather than as an inactive ingredient. For products in which it is used only as a formulation aid, the FDA Inactive Ingredient Database may be relevant, subject to route, dosage form, and maximum potency considerations (FDA, 2024b).

The Drug Master File pathway can support confidential manufacturing information for a supplier. A Type II Drug Master File may cover the manufacture, processing, packaging, and testing of dextrose monohydrate used in an applicant's drug product. The DMF does not itself create market exclusivity, but it can reduce the regulatory burden for customers and strengthen supplier retention.

What patents protect dextrose monohydrate products?

Conventional dextrose monohydrate is an established chemical substance with no meaningful composition-of-matter exclusivity for ordinary pharmaceutical use. The commercial patent opportunity is in formulation, delivery, manufacturing, packaging, or combination claims.

Patent categories with potential value

Patent category	Potential claim subject matter	Expected strength
Composition of matter	Dextrose monohydrate itself	Very low for established products
Formulation	Stabilized injectable solution or oral dosage form	Moderate if technically differentiated
Delivery system	Dual-chamber bag, autoinjector, pump, or controlled administration	Moderate to strong
Manufacturing process	Crystallization, drying, particle engineering, or impurity control	Moderate if non-obvious and reproducible
Packaging	Moisture-control or oxygen-control system	Low to moderate
Combination product	Dextrose with electrolytes, amino acids, vitamins, or rescue medicines	Moderate
Method of use	Specific hypoglycemia, nutrition, or emergency-use protocol	Variable
Quality-control method	Analytical method or release specification	Usually limited
Device integration	Closed-system transfer or infusion technology	Potentially strong

A patent claiming only the use of dextrose monohydrate as a carbohydrate source is unlikely to create durable protection without a specific, non-obvious therapeutic application. A stronger position may arise from a defined formulation that improves stability, reduces vein irritation, minimizes precipitation, or enables an operational benefit in hospital administration.

When does dextrose monohydrate lose exclusivity?

Dextrose monohydrate has no practical loss-of-exclusivity event comparable to a modern patented small-molecule drug. The underlying substance is long established, and competing manufacturers can generally enter with compliant material or approved products.

Market entry is constrained by:

• FDA approval or applicable abbreviated pathway
• Current Good Manufacturing Practice compliance
• Sterile manufacturing capacity
• Drug listing and labeling requirements
• Customer qualification
• Supply-chain validation
• Pharmacopeial testing
• Hospital contracting
• Container and closure qualification

For a new dextrose injection, the relevant barrier is regulatory and operational execution, not expiration of a basic dextrose patent. Product-specific patents may expire at different times, but those patents generally protect a delivery system, formulation, combination, or manufacturing process rather than glucose itself.

What is the Orange Book status of dextrose products?

The FDA Orange Book lists approved drug products and patent information for products subject to FDA patent-listing requirements. Dextrose products may appear through approved prescription drug applications, including injectable products, but Orange Book status must be assessed at the product and application level rather than inferred from the ingredient name.

The principal diligence questions are:

• Whether the specific product has an NDA or ANDA listing
• Whether patents are listed for that application
• Whether any listed patent is directed to the formulation, method of use, or device
• Whether the proposed generic product would require a Paragraph IV certification
• Whether the reference product has unexpired regulatory exclusivity
• Whether labeling differences affect a section viii or other abbreviated strategy

Because conventional dextrose has no active composition-of-matter patent, Paragraph IV risk is usually product-specific. A challenge would generally target a listed formulation, method-of-use, packaging, or delivery patent. The existence of a dextrose product in the Orange Book does not establish that dextrose monohydrate itself is patent-protected.

Which companies compete in the dextrose injection market?

Competition is concentrated among large hospital-product manufacturers, generic injectable companies, and contract manufacturers. The competitive set can include:

• Baxter International
• B. Braun
• Fresenius Kabi
• Pfizer and Hospira
• ICU Medical
• Hikma Pharmaceuticals
• Sagent Pharmaceuticals
• Regional sterile-injectable manufacturers
• Private-label and contract manufacturing organizations

The market is divided by hospital contracts, national distribution, shortage performance, manufacturing redundancy, product presentation, and quality history. A low-cost supplier without sterile-fill scale may struggle to convert dextrose monohydrate into a commercially relevant finished product.

Competitive comparison

Business model	Capital intensity	Differentiation	Main barrier
Bulk dextrose monohydrate supplier	Low to moderate	Purity, price, reliability	Commodity pricing
Oral glucose product marketer	Moderate	Taste, dose, packaging, channel	Consumer and clinical distribution
Sterile dextrose injection manufacturer	High	Fill-finish, bag formats, availability	FDA compliance and capacity
Premixed nutrition supplier	High	Stability, convenience, formulation	Complex manufacturing and validation
Excipient-system developer	Moderate	Processing and dosage-form performance	Customer adoption and patentability
Device-integrated product company	High	Administration and workflow	Device regulation and hospital conversion

What formulation patents and method-of-use opportunities exist?

The most credible intellectual-property opportunities involve a specific technical problem.

Formulation opportunities

Potential formulation programs include:

• Low-excipient dextrose injections with improved chemical stability
• High-concentration products optimized for central-line delivery
• Dextrose-electrolyte formulations with reduced precipitation risk
• Ready-to-use parenteral nutrition components
• Powdered oral glucose products with improved moisture resistance
• Chewable tablets with faster disintegration
• Pediatric glucose formulations with controlled sweetness
• Unit-dose products designed for emergency carts
• Freeze-dried or concentrated products requiring reconstitution

A patent application should define a measurable benefit, such as improved shelf life, reduced impurity formation, improved dissolution, reduced caking, or greater dose uniformity. Generic claims to “a pharmaceutical composition comprising dextrose” will face substantial validity and prior-art risk.

Method-of-use opportunities

Method-of-use claims may address:

• Treatment of defined hypoglycemia populations
• Emergency glucose rescue protocols
• Dextrose administration in selected nutrition regimens
• Use in patients with specified renal, hepatic, or metabolic conditions
• Pediatric or neonatal administration methods
• Dosing linked to a monitoring or infusion algorithm

These claims are commercially narrower than broad composition claims. Their value depends on clinical adoption, label alignment, enforceability, and the ability to detect infringement.

What manufacturing and intellectual-property barriers affect entry?

Dextrose monohydrate is commonly manufactured through glucose crystallization, separation, drying, milling, and packaging. Manufacturing differentiation may involve:

• Crystallization control
• Hydrate-state consistency
• Color and impurity reduction
• Low endotoxin processing
• Particle-size engineering
• Reduced bioburden
• Improved flow and compaction
• Packaging that limits moisture uptake

For injectable use, the finished product requires sterile solution preparation and validated aseptic or terminal-sterilization processes. The sterile-fill facility, not the glucose chemistry, is often the principal entry barrier.

Supply reliability is commercially important because hospital injectables can face shortages when a small number of facilities experience quality events, equipment failures, or raw-material disruptions. A supplier with multiple qualified manufacturing sites, redundant packaging, and stable release testing can command a premium over spot-market material.

What licensing deals are available for dextrose monohydrate products?

Traditional molecule licensing is unlikely to generate substantial value because dextrose monohydrate is established and widely available. More realistic transaction structures include:

• Exclusive distribution of a sterile dextrose product by geography
• Supply agreements with minimum purchase commitments
• Contract manufacturing for hospital products
• Licensing of a moisture-resistant oral dosage platform
• Co-development of premixed nutrition products
• Technology transfer for sterile bag filling
• Private-label commercialization
• Regional rights for emergency glucose products
• Licensing of a device-integrated infusion system

The strongest licensing asset is usually a finished product, manufacturing platform, regulatory dossier, or hospital distribution position. A raw-material license alone is less defensible unless it includes a validated quality advantage or protected process.

What generic entry risks exist for dextrose products?

Generic entry risk is high for conventional dextrose injections and oral glucose products because:

• The active ingredient is well established.
• The clinical use is familiar.
• Formulations are relatively simple.
• Multiple suppliers can produce compendial-grade material.
• Substitution is often driven by price and availability.

Risk is lower for products with:

• Complex delivery devices
• Proprietary container systems
• Combination nutrition formulations
• Difficult sterile manufacturing
• Product-specific stability requirements
• Protected manufacturing processes
• Specialized pediatric or emergency packaging

A generic entrant may pursue an ANDA where a suitable reference product and regulatory pathway exist. If listed patents remain, the applicant may submit a Paragraph IV certification or use a non-infringing approach where available. The practical timing of launch depends on FDA review, patent litigation, settlement terms, and the applicant's ability to obtain validated commercial-scale supply.

How strong is the patent estate for dextrose monohydrate?

The patent estate for the underlying ingredient is weak because the chemical substance is old and broadly available. The estate for a differentiated product can be moderate if it combines:

1. A clinically relevant formulation benefit.
2. Narrow but defensible composition claims.
3. Supporting process claims.
4. Device or packaging claims.
5. Clinical or stability data.
6. A regulatory label that aligns with the protected use.

Patent-strength assessment

Asset	Patent strength	Commercial defensibility
Commodity dextrose monohydrate	Low	Price, quality, supply
USP-grade injectable raw material	Low to moderate	Qualification and reliability
Standard dextrose injection	Low	Manufacturing scale and contracts
Proprietary premixed nutrition formulation	Moderate	Formulation and operational convenience
Moisture-stable oral glucose tablet	Moderate	Performance and brand
Integrated glucose delivery device	Moderate to strong	Device and workflow claims
Novel crystallization or particle process	Moderate	Process secrecy and patent claims
Hospital shortage-response supply platform	Low patent value	Operational execution

What is the commercial opportunity by product segment?

Bulk pharmaceutical ingredient

Bulk dextrose monohydrate is a scale business. Margins depend on raw-material costs, crystallization yield, energy consumption, testing, packaging, and freight. The best customers are sterile-injectable manufacturers, nutrition-product companies, and global excipient distributors.

Sterile injectable products

Sterile dextrose products offer greater value than bulk material because they require regulatory approval, specialized facilities, and validated packaging. Opportunities include small-volume emergency products, premixed bags, concentrated formulations, and regional shortage supply.

Oral glucose products

Oral glucose products can support higher gross margins through branding, convenience, flavor, unit-dose packaging, and pharmacy or institutional distribution. The principal markets include diabetes care, emergency medical services, hospitals, sports nutrition, and pediatric care.

Co-processed excipient systems

A co-processed dextrose platform could address direct compression, flow, moisture resistance, or rapid disintegration. This segment offers the clearest opportunity for formulation-led intellectual property, provided performance data demonstrate a meaningful advantage over standard glucose excipients.

Bioprocessing and cell culture

High-purity glucose monohydrate can be sold into bioprocessing, diagnostics, and cell-culture applications. This market may impose tighter requirements for trace metals, endotoxins, microbial control, and lot-to-lot consistency. The regulatory classification differs from finished pharmaceutical use, but GMP documentation and supply assurance remain important.

What revenue exposure and market risks should investors assess?

Revenue exposure is driven by volume and manufacturing utilization rather than by patent-protected price. Key risks include:

• Commodity price competition
• Hospital purchasing consolidation
• Raw-material and energy costs
• Sterile manufacturing disruptions
• Product recalls
• Endotoxin or particulate failures
• Regulatory warning letters
• Customer qualification delays
• Substitution with anhydrous dextrose or other carbohydrate sources
• Declining use of certain nutrition or irrigation formats

The most resilient business model combines several revenue streams: compendial raw material, sterile finished products, oral dose products, and technical services. Dependence on one large injectable customer or one manufacturing site creates material commercial risk.

Key Takeaways

• Dextrose monohydrate is both an active pharmaceutical ingredient and a functional excipient.
• Conventional dextrose monohydrate has little practical composition-of-matter patent value.
• Injectable products create greater commercial barriers than bulk material because of sterility, validation, packaging, and regulatory requirements.
• The most credible patent opportunities involve formulations, manufacturing processes, delivery systems, packaging, and defined methods of use.
• Generic entry risk is high for standard dextrose injections and oral glucose products.
• Higher-value opportunities include premixed nutrition products, co-processed oral excipients, unit-dose emergency glucose products, and device-integrated delivery systems.
• Supply reliability, USP or Ph. Eur. compliance, low endotoxin performance, and validated sterile capacity are more important than basic molecule exclusivity.
• Licensing value is concentrated in finished products, regulatory dossiers, manufacturing platforms, and distribution rights.

FAQs

Is dextrose monohydrate the same as glucose monohydrate?

Yes. Dextrose monohydrate is the pharmaceutical term commonly used for D-glucose containing one molecule of water of crystallization.

Can dextrose monohydrate replace anhydrous dextrose?

It can replace anhydrous dextrose only after correcting for molecular weight and water content. The two forms are not equivalent on a weight-for-weight basis.

Is dextrose monohydrate an active ingredient or an excipient?

It can be either. In an intravenous glucose product, it is generally the active ingredient. In a tablet or powder, it may function as a carbohydrate source, diluent, binder, or sweetener.

Does dextrose monohydrate require a Drug Master File?

A Drug Master File is not universally mandatory, but it can protect confidential manufacturing information and simplify regulatory submissions by customers using the material in drug products.

What is the strongest commercial differentiation for pharmaceutical dextrose?

The strongest differentiation is usually sterile manufacturing capacity, reliable supply, specialized packaging, formulation performance, low-endotoxin quality, or integration with an administration device.

References

1. DailyMed. (2024a). Dextrose injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu/

3. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

6. U.S. Food and Drug Administration. (2024c). Drug Master Files guidance for industry. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files-guidance-industry

7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. https://www.usp.org/usp-nf